Back to top
more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$3.09 USD

3.09
2,745,426

-0.30 (-8.73%)

Updated May 8, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

Here's Why You Should Invest in Aquestive (AQST) Stock Now

Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Best Momentum Stock to Buy for December 7th

AQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023.

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Journey Medical (DERM) Up on Update for Skin Disease Candidate

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.

Best Momentum Stocks to Buy for December 1st

LEU, AQST and TM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 1, 2023.

New Strong Buy Stocks for December 1st

AQST, TM, LEU, BWAY and MOD have been added to the Zacks Rank #1 (Strong Buy) List on December 1, 2023.

Best Momentum Stocks to Buy for November 28th

AQST, FMX and MNSO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 28, 2023.

New Strong Buy Stocks for November 28th

AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.

Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know

Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.

New Strong Buy Stocks for November 21st

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know

Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for November 16th

IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.

Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.